Patients With HCV, Chronic Kidney Disease Less Likely to Receive Antivirals
Individuals with CKD and HCV infection achieve high cure rates with newer anti-HCV treatment regiments.
The combination of HBsAg and HBcrAg had the greatest predictive value for HBeAg seroconversion.
Sofosbuvir-based regimens administered for HCV recurrence after liver transplantation are safe for the kidneys.
Tailoring treatment based on baseline resistance-associated substitutions status may optimize hepatitis C virus outcomes.